Immunology
Immunology
Search
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Partnering Days
Partnering Days
Advocating for More Patient-Centered Mental Health Care
Advocating for More Patient-Centered Mental Health Care
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Championing Novel Science
Championing Novel Science
CIA Reporting Requirements
CIA Reporting Requirements
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board
Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Sunshine Act Compliance
Sunshine Act Compliance
Respiratory
Respiratory
Work Care Consortium | COVID-19 | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
FDA Grants BTD for Investigational Treatment of CIAS | BI US
Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.
Mental Health disorders
Mental Health disorders
Clinical Trials
Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases